News Website

Breakthrough treatment combines immunotherapy and chemotherapy - National Health Executive

Breakthrough treatment combines immunotherapy and chemotherapy National Health Executive

Published: Aug. 7, 2025, 8:48 a.m.

Read Full Article

Lenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights - Cureus

Lenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights Cureus

Published: July 30, 2025, 7:21 a.m.

Read Full Article

Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer - Medical Xpress

Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer Medical Xpress

Published: June 2, 2025, 6:20 p.m.

Read Full Article

Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer | Newswise - Newswise

Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer | Newswise Newswise

Published: June 2, 2025, 2:25 p.m.

Read Full Article

Real-World Analysis Informs Future Directions for Evaluating Dostarlimab/Chemotherapy in Advanced Endometrial Cancer - OncLive

Real-World Analysis Informs Future Directions for Evaluating Dostarlimab/Chemotherapy in Advanced Endometrial Cancer OncLive

Published: May 28, 2025, 2:28 p.m.

Read Full Article

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - BioSpace

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 18, 2025, 5:25 a.m.

Read Full Article

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - The Malaysian Reserve

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 18, 2025, 12:16 a.m.

Read Full Article

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Yahoo Finance

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 17, 2025, 5:15 p.m.

Read Full Article

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Newswire.ca

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 17, 2025, 5:15 p.m.

Read Full Article

Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of CRT vs Chemotherapy for Locally Advanced Endometrial Carcinoma - MedPage Today

Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of CRT vs Chemotherapy for Locally Advanced Endometrial Carcinoma MedPage Today

Published: April 9, 2025, 3:15 p.m.

Read Full Article

Latest Articles

Breakthrough treatment combines immunotherapy and chemotherapy - National Health Executive

Lenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights - Cureus

Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer - Medical Xpress

Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer | Newswise - Newswise

Real-World Analysis Informs Future Directions for Evaluating Dostarlimab/Chemotherapy in Advanced Endometrial Cancer - OncLive

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - BioSpace

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - The Malaysian Reserve

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Yahoo Finance

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Newswire.ca

Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of CRT vs Chemotherapy for Locally Advanced Endometrial Carcinoma - MedPage Today

Subscribe to Our Newsletter